Apollo and Toto May Make Offer for Atlantia Highway Unit: Papers
Apollo Global Management Inc. and Toto Holding SpA may offer to buy control of Atlantia SpA’s Italian toll-road unit, La Stampa and other Italian newspapers reported Sunday.
Bloomberg · 5d ago
Covis Group Completes Acquisition of AMAG Pharmaceuticals
Covis Group S.à r.l. ("Covis") today announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger. The combined organization will operate as part of the Covis Pharma Group and will be led by Covis CEO Michael Porter.
PR Newswire · 11/16/2020 14:20
Statement by Minister Chagger on Diwali
Today, members of Hindu, Jain, and Buddhist communities in Canada and around the world celebrate DiwaliOTTAWA, ON, Nov. 14, 2020 /CNW/ - Today, members of Hindu, Jain, and Buddhist communities in Canada will celebrate Diwali—also known as the Festival of Lights.
CNW Group · 11/14/2020 14:30
AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: Should You Buy?
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/30/2020 17:30
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 10/15/2020 12:03
Covis Group S.à r.l. Announces Commencement Of Tender Offer For All Outstanding Shares Of AMAG Pharmaceuticals, Inc.
LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 /CNW/ -- Covis Group S.à r.l. ("Covis") announced the commencement of a cash tender offer to purchase all of the outstanding shares
Benzinga · 10/15/2020 11:32
AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena®, the only FDA-approved treatment, along with its equivalent generics, to reduce preterm birth. Makena was approved in 2011, based on the landmark NICHD MFMU trial by Meis et al. A second, FDA-required trial (PROLONG) predominantly enrolled women outside of the U.S., in countries with markedly lower rates of preterm birth. The PROLONG trial did not show a difference between treatment and vehicle arms with respect to preterm birth or neonatal outcome. However, maternal and fetal safety was re-affirmed. Today’s hearing request will be followed by a submission of supporting documentation to the FDA. That submission will provide further detail on the company’s reasoning for a hearing, recognizing clinicians’ decade-long use of this treatment and the public health implications of withdrawing its approval. At this time, it is important to note that Makena remains approved and available and the product label remains unchanged.“We believe it is in the best interest of these high-risk pregnant patients to allow their obstetrical provider to determine whether to use Makena, following the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) guidelines, as well as their own long-standing clinical experience. The continued widening of maternal and infant health disparities among minority and disadvantaged communities, and the potential return to compounded versions of Makena are concerning,” said AMAG CEO Scott Myers. “We remain committed to preserving access to the FDA-approved therapy, as there are no other evidence-based options for these vulnerable patients.”AMAG submitted a proposal earlier this year to the FDA, requesting to meet and discuss two studies intended to define the patient population who would most benefit from therapy: a retrospective study using real world evidence, and a prospective, primary data collection study. FDA declined the request to meet, stating it was premature. AMAG announced in August that it was beginning the first part of the retrospective study.Covis Pharma has entered into a transaction to acquire AMAG, which is subject to customary closing conditions including the tender offering and is expected to close in November.Commenting on AMAG’s hearing request, Covis Pharma CEO Michael Porter said, “We support the efforts by AMAG to preserve patient access to this important treatment option. AMAG and Covis believe in Makena’s efficacy for those at risk for recurrent preterm birth, which are often vulnerable patient groups. We respectfully believe that further study is necessary before precipitously withdrawing the product from the market and are prepared to help formulate and implement appropriate study parameters for additional review of its efficacy.”ACOG issued a statement in response to FDA’s proposed withdrawal, noting that the need for an effective preterm birth treatment is great. As ACOG further recognized, Makena and its associated generics represent the only treatment currently available to obstetrician-gynecologists to help prevent this condition. ACOG states that their treatment recommendations remain unchanged at this time.ABOUT AMAG AMAG is a commercial-stage biopharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas. For additional company information, please visit Looking Statements This press release contains forward-looking information about AMAG Pharmaceuticals, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, statements regarding plans to submit, and expectations for, supporting documentation to the FDA; beliefs that it is in the best interest of patients to allow access to Makena; beliefs about maternal and infant health disparities among minority communities and the return to compounded versions of Makena, and that there are no other evidence-based options; beliefs, including beliefs attributed to other groups, in Makena’s efficacy for those at risk, including that further study should be undertaken into the efficacy of Makena before taking action to withdraw the product from the market and the ability of AMAG’s efforts to preserve patient access to Makena; expectations for working towards formulating and implementing appropriate study parameters to be undertaken to confirm Makena’s efficacy after the tender offer and merger transaction between Covis and AMAG closes, and expectations for the recently announced tender offer and merger transaction are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.Such risks and uncertainties include, among others, risks and uncertainties related to the path forward for Makena and our ability to successfully and timely secure a hearing and compile information that might be helpful to the FDA; the possibility that our request for a hearing could be denied, or that the FDA will withdraw marketing approval for Makena even following such a hearing (or before or during the pendency of the hearing and deliberation), the pursuit and planning of which could be costly and distracting to management, the risks related to the pending tender offer and merger transaction (including as described in our Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) on October 1, 2020), and those other risks identified in AMAG’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2019 (as amended), its Current Reports on Form 8-K, its Quarterly Reports on Form 10-Q, including for the quarters ended March 31, 2020 and June 30, 2020, and in any subsequent filings with the SEC, which are available at the SEC’s website at Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.AMAG Pharmaceuticals®, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, Inc. Makena® is a registered trademark of AMAG Pharma USA, Inc.AMAG CONTACT: Investors & Media: Rushmie Nofsinger (617) 498-2806
GlobeNewswire · 10/14/2020 21:11
AMAG Pharma Reports Request For Hearing To Maintain Makena As Treatment Option For Clinically-Indicated Pregnant Patients
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of
Benzinga · 10/14/2020 20:11
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMAG. Analyze the recent business situations of AMAG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMAG stock price target is 11.96 with a high estimate of 13.75 and a low estimate of 5.00.
Institutional Holdings
Institutions: 197
Institutional Holdings: 47.28M
% Owned: 136.15%
Shares Outstanding: 34.73M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Pharmaceuticals & Medical Research
Key Executives
Chairman/Independent Director
Gino Santini
President/Chief Executive Officer/Director
Scott Myers
Chief Financial Officer
Brian Piekos
Chief Operating Officer/Executive Vice President
Anthony Casciano
Chief Human Resource Officer/Senior Vice President
Kelly Schick
Senior Vice President/Director of Sales/Director of Marketing
Tony Casciano
Executive Vice President/General Counsel/Secretary
Joseph Vittiglio
Vice President
Nancy Griffith
Independent Director
John Fallon
Independent Director
Paul Fonteyne
Independent Director
David Johnson
Independent Director
Cooper Russell
Independent Director
Kathrine O'Brien
Independent Director
Anne Phillips
Independent Director
Davey Scoon
Independent Director
James Sulat
No Data

Webull offers kinds of AMAG stock information, including NASDAQ:AMAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMAG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMAG stock methods without spending real money on the virtual paper trading platform.